Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) closed the day trading at $11.20 down -43.26% from the previous closing price of $19.74. In other words, the price has decreased by -$43.26 from its previous closing price. On the day, 9.65 million shares were traded. EYPT stock price reached its highest trading level at $14.0 during the session, while it also had its lowest trading level at $11.0601.
Ratios:
For a better understanding of EYPT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.39 and its Current Ratio is at 5.45. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JP Morgan on January 22, 2024, initiated with a Overweight rating and assigned the stock a target price of $35.
On November 02, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $20.
On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $33.Robert W. Baird initiated its Outperform rating on April 21, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 18 ’24 when Cormorant Asset Management, LP bought 581,765 shares for $18.03 per share. The transaction valued at 10,489,446 led to the insider holds 7,475,000 shares of the business.
Jones David Scott sold 209 shares of EYPT for $5,954 on Feb 02 ’24. The SVP & Chief Commercial Officer now owns 37,962 shares after completing the transaction at $28.49 per share. On Jan 26 ’24, another insider, Paggiarino Dario A., who serves as the Chief Medical Officer of the company, sold 49,325 shares for $25.66 each. As a result, the insider received 1,265,539 and left with 36,505 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EYPT now has a Market Capitalization of 1032752000 and an Enterprise Value of 232523872. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.13 while its Price-to-Book (P/B) ratio in mrq is 2.06. Its current Enterprise Value per Revenue stands at 5.053 whereas that against EBITDA is -3.168.
Stock Price History:
Over the past 52 weeks, EYPT has reached a high of $30.99, while it has fallen to a 52-week low of $5.67. The 50-Day Moving Average of the stock is -48.43%, while the 200-Day Moving Average is calculated to be -31.60%.
Shares Statistics:
Over the past 3-months, EYPT traded about 997.66K shares per day on average, while over the past 10 days, EYPT traded about 1102190 shares per day. A total of 49.04M shares are outstanding, with a floating share count of 46.63M. Insiders hold about 6.42% of the company’s shares, while institutions hold 98.01% stake in the company. Shares short for EYPT as of 1713139200 were 6536042 with a Short Ratio of 6.55, compared to 1710460800 on 6579352. Therefore, it implies a Short% of Shares Outstanding of 6536042 and a Short% of Float of 17.889999.
